Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Income Statement

Financials in millions USD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020	Oct 31, 2019
Revenue	0	0.21	0	0.51	0	0.25
Revenue Growth (YoY)	-	-	-	-	-	-77.53%
Cost of Revenue	0	0.16	0	0.39	0	0.17
Gross Profit	0	0.05	0	0.13	0	0.08
Selling, General & Admin	7.27	6.29	7.17	7.07	5.6	5.66
Research & Development	5.7	4.77	6.7	6.19	4.38	5.47
Other Operating Expenses	0	0	0	0	0	0.84
Operating Expenses	12.97	11.06	13.88	13.26	9.98	11.97
Operating Income	-12.97	-11.01	-13.88	-13.14	-9.98	-11.89
Other Expense / Income	-1.38	-1.2	-0.28	-0.18	0.04	-0.24
Pretax Income	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
Net Income	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
Shares Outstanding (Basic)	32	31	30	29	22	20
Shares Outstanding (Diluted)	32	31	30	29	22	20
Shares Change	3.18%	2.00%	6.28%	28.57%	12.33%	12.29%
EPS (Basic)	-0.37	-0.32	-0.45	-0.45	-0.45	-0.59
EPS (Diluted)	-0.37	-0.32	-0.45	-0.45	-0.45	-0.59
Free Cash Flow	-7.18	-6.21	-6.49	-4.9	-6.19	-4.92
Free Cash Flow Per Share	-0.23	-0.20	-0.21	-0.17	-0.28	-0.25
Gross Margin	-	23.33%	-	24.80%	-	33.50%
Operating Margin	-	-5243.33%	-	-2565.63%	-	-4756.00%
Profit Margin	-	-4671.90%	-	-2530.08%	-	-4658.82%
Free Cash Flow Margin	-	-2956.67%	-	-957.62%	-	-1966.75%
EBITDA	-11.55	-9.77	-13.55	-12.89	-9.93	-11.6
EBITDA Margin	-	-4650.00%	-	-2518.36%	-	-4639.80%
Depreciation & Amortization	0.05	0.05	0.04	0.06	0.09	0.05
EBIT	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
EBIT Margin	-	-4671.90%	-	-2530.08%	-	-4658.82%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).